A protocol-specified exploratory analysis was performed of clinicopathological factors associated with sensitivity to treatment including demographic data, number of prior therapies, sites of metastatic disease, and mutational data from circulating tumor DNA (ctDNA), specifically TP53 status (Supplementary Information). This evidence concerns the gene TP53 and metastatic neoplasm.